Personalized vaccine for high-risk triple-negative breast cancer
Part of Cancer, Skin clinical trials.
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help prevent your high-risk triple-negative breast cancer from coming back. It is for people who had significant tumor left after standard chemotherapy and surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You had stage II or III triple-negative breast cancer (ER/PR less than 10%, HER2-negative).
- You completed standard chemotherapy and surgery, but there was still a significant amount of tumor left (doctors call this 'residual disease').
- You are 18 years or older.
- You are generally healthy, with a performance status that allows for daily activities (ECOG 0 or 1).
- You have enough leftover tumor tissue from your surgery that can be used for genetic testing.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether using tumor “genetics” (information from your biopsy) to guide radiation planning can improve treatment for triple-negative breast cancer. It may help by aiming radiation more precisely while still using standard approaches where needed.
This trial tests a personalized cancer vaccine for triple negative breast cancer. It is given alongside standard chemotherapy and immunotherapy to help your immune system fight the cancer.
This trial tests a personalized cancer vaccine (NECVAX-NEO1) given along with standard chemotherapy and immunotherapy before surgery for patients with triple-negative breast cancer. The vaccine is customized to target specific mutations in your tumor, aiming to boost your immune system and improve treatment outcomes.
This trial tests a new personalized treatment approach (mRNA-lncRNA model) for people with low-risk, early-stage triple-negative breast cancer who have already had surgery. It aims to see if a less intense treatment can work just as well as standard care.
This trial tests a personalized treatment where your own immune cells are modified to recognize and attack cancer cells that have a specific marker called NY-ESO-1. It is for people with triple-negative breast cancer that has not responded to at least two prior treatments.
This Phase 2 trial tests a treatment plan for triple-negative breast cancer that has come back or kept progressing after prior immunotherapy (sometimes along with targeted therapy or chemotherapy). It may help by trying to make the cancer more controllable when it has become resistant to earlier treatment.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.